The present review aims to highlight the major recent advances in transplantation with regards to basic, translational, and clinical research.
INTRODUCTION
This article provides an up-to-date review of our current understanding of alloimmunity and their translation on to the clinical management of organ transplant. We discuss the current efforts in understanding the basic mechanisms of T-cell allospecificity, memory response, antibody-mediated allograft injury, and immune regulation. Furthermore, we highlight the recent technical advances in gene editing technologies and microparticle-based drug delivery, which are causing great excitement as novel potential therapeutic strategies.
Understanding the mechanisms of allorecognition and T-cell allospecificity
The immune response following transplantation is initiated upon recognition of foreign major histocompatibility complex (MHC) molecules by the recipient's immune system via either the 'direct' or 'indirect' pathway. Although donor MHC-peptide complexes are directly recognized by recipients' T cell in the former, allo-MHC is processed and represented by recipient antigen-presenting cells (APCs) in the indirect pathway, which plays a dominant role in the long term based on the continuous shedding of alloantigen from the graft. By using an adoptive transfer model of transgenic T cells in a murine chronic cardiac transplant model, Ali et al. [1 & ] elegantly showed that the direct pathway CD4 þ T cells are short lived, mostly because of the quick elimination of donor-derived APCs, whereas the indirect pathway CD4 þ T-cell responses are persistent and heterogeneous in terms of duration and sites, depending on the targeted alloantigen: donor MHC I-specific responses taking place in allograft parenchyma last long, whereas anti-MHC II responses decay earlier because of donor APCs eradication. These findings highlight the importance of restraining the indirect allorecognition, in particular against donor MHC class I molecules, to prevent chronic cellular-mediated rejection.
The specificity of the T-cell receptor (TCR), especially in terms of the cross-reactivity to different peptide-MHC complexes, is an important topic in transplantation as it may explain the presence of memory response in the absence of prior donor MHC exposure. Nelson et al.
[2] recently demonstrated that antigenic peptides binding a same MHC II molecule (I-A b ) only require five amino acids in common to trigger cross-reactivity to the same TCR [2]. They showed in mice that a naïve T-cell population specific to self-tissue-restricted antigen that was incompletely deleted could be engaged by bacterial-derived peptides sharing contact amino acids with the self-peptides, thus triggering autoimmunity. This similar cross-reactivity phenomenon could explain why some patients can develop anti-human leukocyte antigen (HLA) antibodies despite no prior sensitizing events (i.e., pregnancy, transplantation, or blood transfusion). The ability to identify allospecific T cells against the donor organ has been a major challenge in transplantation. Morris et al. [3] established an assay to identify donor-specific T-cells clones prior to transplant and track their deletion in patients who underwent combined kidney and bone marrow transplantation for tolerance induction. In this study, carboxyfluorescein succinimidyl ester-labeled recipient's peripheral blood mononuclear cells were cultured with irradiated donor peripheral blood mononuclear cells, proliferating T-cell subsets were subsequently isolated, and TCR clones characterized by deep sequencing to determine the donor-specific TCR clones. Clonal deletion of donor-reactive T cells was present in tolerant, but not in nontolerant, combined kidney and bone marrow transplantation patients, supporting the monitoring of donorspecific clones as a potential biomarker of the tolerance development posttransplantation.
Challenges in targeting the memory response
Targeting memory T cells pose a great obstacle to transplantation as they may trigger robust alloimmune responses with lower activation thresholds, and are less dependent on costimulatory signals or cytokines for full activation, thus leading to greater resistance to current available immunosuppressive drugs. When compared with mice, humans carry a much more diverse immune repertoire as a result of an outbred nature and multiple immunological challenges, such as infections and vaccinations, exposed during a lifetime. Recently, Masopust's group pointed to certain limitations of the use of laboratory mice to study immune responses, based on the lack of memory T cells and significant differences in immune phenotype when compared with an adult human immune system [4 && ]. Specifically, laboratory mice had an immune system very similar to a human neonate, whereas microbial-experienced mice -such as those found in pet storespresented a similar immune cell composition to adult humans. By cohousing laboratory mice with pet store mice, the authors could successfully expand the memory phenotype of laboratory mice, indicating that this attractive strategy may allow murine immunology research to be performed with greater similarity to adult humans.
The role of tissue-resident memory T cells in target organ protection is also being increasingly recognized. Steinert et al.
[5] observed that memory T cells stay local, and survey and patrol nonlymphoid solid organs. After restimulation, local immune responses are carried by tissue-resident memory T cells, instead of recirculating T cells. These findings may explain why antidonor memory T cells are so difficult to be targeted once they have been generated, as T cells may not need to recirculate to secondary lymphoid organs to be fully activated prior to causing graft injury.
Cross talk between innate and adaptive immunity
Innate immunity is primarily a nonantigen-specific immune response driven by tissue injury, such as ischemia or infection, and it is capable of triggering and enhancing adaptive immunity. Among innate
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immune cells, dendritic cells are the major group of APCs during the alloimmune responses and are crucial for T-cell activation. Recent studies highlight the importance of innate immune cells in shaping the alloimmune response: Batal et al. [6] demonstrated the clinical significance of intragraft dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin þ dendritic cells in 105 'for-cause' allograft biopsies. DC-SIGN is involved in dendritic cell/T-cell clustering, and is required for dendritic cell-initiated proliferation of resting T cells [7, 8] . The authors observed that DC-SIGN þ cell density >3.8 cells/hpf was adversely associated with allograft function and survival (2 year after biopsy, r ¼ À0. 36 , P < 0.001), and with increased proliferation of T cells (Ki67 þ ) and higher inflammation scores (ti2-ti3). Interestingly, DC-SIGN þ cells clustered with lymphocytes were predominantly of recipient origin, especially at the later time points [6] . This observation implies a possibly harmful effect of in-situ DC-SIGN þ dendritic cells on the alloimmune response and provides a rationale for targeting dendritic cells to halt allograft inflammation.
Although the detrimental role of the innate immune cells is increasingly recognized in transplantation, recent studies have demonstrated that myeloid cells may have immunomodulatory properties and inhibit alloreactive T-cell responses in both mice [9, 10] and humans [11] . Conde et al. [12] showed that a population of graft-infiltrating suppressive macrophages was expanded under a CD40L-CD40 blockade protocol in murine cardiac transplantation. Those cells were CD11b þ CSF1R þ Ly6C low Ly6G -CD169 þ and when isolated from tolerized transplanted mice could suppress CD8 T-cells proliferation and expand regulatory T cells (Tregs) in vitro in an IL-10-dependent manner.
Molecular signature of acute rejection and chronic allograft injury
Delineating molecular signatures of acute and chronic rejection may improve classification and provide hints to the development of more effective treatments [13, 14] . By incorporating a 'molecular T cell-mediated rejection (TCMR) score' based on transcriptional signature captured by microarray to conventional histological analyses in 703 for cause biopsies, Reeve et al. [15] suggested a new diagnosis algorithm to better categorize TCMR. Interstitial inflammation and tubulitis were the key histologic features compared with arteritis [15] in TCMR. Similarly, Modena et al. [16] applied microarray platform to a collection of 234 allograft biopsy samples, looking specifically at chronic changes in comparison with acute rejection. The pathway analyses of this 'molecular biopsy signature' revealed that, by comparing the transcriptional features of interstitial fibrosis/tubular atrophy (IFTA) with acute rejection, there was a surprising overlap in gene expression patterns among those histologically distinct pathological processes [commonly upregulated genes included immunoglobulin heavy and light chains, lactotransferrin, serpin family A member 3, and chemokine (C-X-C motif) ligand 9, etc.]. Interestingly, even in IFTA biopsy samples without histological evidence of inflammation, the expression of acute rejection-associated genes correlated with a higher risk of graft loss at 5 or more years, suggesting that most IFTA samples have subclinical and possibly ongoing immune-mediated injury. Whether targeting this inflammation would slow down progression remains to be determined.
Modulators of regulatory T cells in transplantation and allograft tolerance
Regulatory T cells have been explored as important players in immune regulation and as promising therapeutic targets. However, their exact suppressive mechanisms and interaction with other cells are not fully understood, especially in the transplant context. Bézie et al. [17] demonstrated that IL-34 is both a CD4 þ and CD8 þ Treg-derived cytokine that can abrogate alloimmune responses. IL-34 can be expressed by rat CD8 þ CD45RC low Tregs and both human CD4 þ CD45RC low Foxp3 þ and CD8 þ CD45RC low Foxp3 þ Tregs, and this cytokine was involved in their suppressive functions in inhibiting antidonor immune responses in vitro. Overexpression of IL-34 in vivo inhibited the production of donor-specific antibodies (DSA) and induced both CD4 þ and CD8 þ , highly suppressive Tregs in a cardiac allograft rat model. Macrophages were required to induce these Tregs, demonstrating a cross talk between these two cell populations. Overall, IL-34 appears to be an important regulatory cytokine and a potential therapeutic target to promote immune regulation.
Tolerance in small animals can be relatively easily achieved through multiple different strategies, whereas infection has been shown to precipitate rejection, suggesting the unstable nature of transplant tolerance. For example, Miller et al. [18] showed that under a tolerance induction protocol with anti-CD40L (CD154) and donor-specific transfusion, tolerant mice recipients could lose their cardiac allograft after an infection with Listeria monocytogenes. Infection-triggered alloreactivity was characterized by an increase in antidonor effector responses, but this response was not because of antibacterial T cells cross-reacting with donor antigens. Furthermore, retransplantation of a second donor-matched allograft after resolution of the infection led to long-term tolerance without any additional immunosuppressive therapy and restoration of allospecific tolerance was dependent on Tregs [18] . Interestingly, tolerant mice could mount a memory response to the bacterial pathogen, demonstrating that the transient loss of the tolerance was specific to donor antigens. Thus, immunological tolerance against the allograft is only transiently lost in the setting of infection but can be restored spontaneously once the infection is controlled.
In addition to infection, our group has recently demonstrated that high-salt diet is capable of accelerating rejection. Using a MHC class II-mismatched cardiac transplant model, we showed that a highsalt diet (3.15% Na) when compared with normal diet (0.28%) alters immune regulation and precipitates allograft rejection [19] . This phenomenon was related to a reduction in Tregs both in the periphery and in the allograft. Deleterious effect on Tregs occurred via activation of serum/glucocorticoidregulated kinase 1 (SGK1) by salt, leading to downregulation of transcription factors forkhead box O (Foxo)1/Foxo3 critical for Treg homeostasis. Similarly, a high-lipid diet has been recently shown to precipitate rejection in preclinical models [20] [21] [22] . Therefore, infection and environmental exposures, such as high-salt or high-fat diet, may negatively affect immune regulation by impacting Treg function and precipitate rejection.
Targeting B cells in transplantation
Targeting B cells with rituximab in transplantation and autoimmunity has yielded mixed results. Using an allogeneic, syngeneic cardiac transplant model, and TLR agonists, Laws et al. [23] demonstrated that inflammation mitigates B-cell depletion by altering the pharmacokinetics and pharmacodynamics of anti-CD20 mAb therapy leading to accelerated reconstitution of the B-cell pool. A single dose of anti-CD20 mAb at the time of transplant fails to maintain B-cell depletion. Furthermore, intravenous immunoglobulin (IVIG) coadministration with anti-CD20 mAb significantly shortened the half-life of the mAb and led to accelerated B-cell recovery. Repeated dosing restored B-cell depletion in secondary lymphoid organs and delayed graft rejection, independent of alloantibody production. Overall, these studies demonstrate the importance of further clinical studies of the pharmacokinetics and pharmacodynamics of mAb treatment in inflammatory conditions and highlight the deleterious effect of IVIG when given with anti-CD20 and the relevance of redosing of anti-CD20 for effective B-cell depletion in alloimmunity. Others have recently demonstrated negative effects of whole B-cell depletion, which may be related to depletion of regulatory B-cell populations. Marino et al. [24] reported a deleterious effect of anti-CD20-mediated B-cell depletion in a murine skin transplant model, by potentially enhancing alloreactive memory T-cell responses and Chandraker et al. [25] presented preliminary results of the Clinical Trials in Organ Transplantation 11 study in heart transplant recipients, in which rituximab was given as induction therapy on days 0 and 12 after transplantation and led to worse coronary vasculopathy at 1 year. Further investigation is needed on how to optimally target B cells in transplantation.
Alloantibody inhibition and complementbinding donor-specific antibody
Despite the use of potent combinations of immunosuppressive agents (calcineurin inhibitor, steroids, mycophenolate mofetil), around 15% of kidney transplant recipients develop DSA at 4 years posttransplant and chronic antibody-mediated rejection is a major cause of long-term graft loss. Therefore, the 7-year follow-up of the Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) [26 && ] was intriguing as it showed that patients treated with belatacept maintenance therapy developed less frequently de novo DSA posttransplant (3.1 and 1.4% on belatacept low intensity and high intensity, respectively, compared with 11.6% on cyclosporine group). There are still some caveats as only a subset of patients originally enrolled in this trial was included in the final analysis and the control group with cyclosporine was different than the current standard of care with tacrolimus. Whether the reduction in DSA development will impact longterm graft survival still remains to be determined but based on prior published data it is highly possible to be beneficial.
To further understand the pathogenicity of alloantibodies, some studies have explored the biochemical features of anti-HLA antibodies, including IgG subclasses and complement-binding capabilities. Lefaucheur et al. [27] analyzed the relationship of IgG subclasses and antibody-mediated rejection (AMR) characteristics: IgG3 DSA was associated with acute AMR with shorter time to rejection, increased microcirculation injury, and C4d deposition, whereas IgG4 DSA was associated with chronic allograft injury and IFTA, suggesting that DSA subclasses may help identify distinct pathological processes mediating AMR. In another study [28] , identification of C1q-binding of DSA in 1016 kidney transplant recipients during the first year after transplant was associated with worse graft outcomes with a 4-fold higher risk of graft loss (hazard ratio, 4.78; 95% confidence interval, 2.69-8.49) when adjusted for clinical, functional, histologic, and immunologic factors. Guidicelli et al. [29] confirmed that 10-year death censored graft survival was lower in patients with C1q-binding de novo DSA detected at both 2 and 5 years (P ¼ 0.002) than in patients without de novo DSA. However, they also observed that long-term exposure to C1q-nonbinding de novo DSA was associated with poor outcomes (P < 0.001), in particular when persistent. Finally, Sicard et al. [30] used another assay of complement binding in 69 biopsy-proven AMR cases and demonstrated that C3d-binding DSA in a flow bead-based assay predicted the graft outcomes at time of AMR, providing a potential risk stratification tool to decide on the aggressiveness of therapeutic strategies to be employed upon AMR diagnosis.
The benefits of desensitization
Transplantation of highly sensitized patients has been challenging. Orandi et al. [31 & ] reported a survival benefit of desensitization in HLA-incompatible live donor kidney transplants when compared with staying on the waitlist. This 22 multicenter study [31 & ] included 1025 highly sensitized kidney transplant recipients (either single antigen screening positive, flow cytometric crossmatch positive, or complement-dependent cytotoxicity crossmatch positive) and showed a 5-year patient survival of 86% in the desensitized live donor group compared with 74% on the group that remained on the waiting list, or was transplanted without desensitization, and 59% on the waiting-list-only control group. Despite those findings, not all sensitized patients can be successfully desensitized. Further exploring this, Yabu et al. [32] compared immune profile of highly sensitized [calculated panel reactive antibody (cPRA) 93-100%] end-stage renal disease patients, who received a desensitization protocol (combination of monthly IVIG, rituximab, bortezomib, and plasmapheresis) and categorized them into desensitization responders (cPRA decrease >5% pre and postdesensitization) and nonresponders, using CyTOF platform (Fluidigm, South San Francisco, CA, US), phospho-signaling, and gene array. They found that the combination of transitional B cells (CD19 þ CD24 þ CD38 þ ) and Tregs (CD4 þ CD25 hi CD127 low ) prior to desensitization could be a good predictor of response to desensitization. Furthermore, the combination of low HLAantigen D relate -CD38 þ CD4 þ T cells and high expression levels of the tumor necrosis factor-associated factor 4 interacting protein 3 (TRAF4IP3) gene may also separate responders from nonresponders. Further validation of these findings is warranted in other sensitized cohorts.
Bioengineering of T-cell receptors and drug-loaded nanoparticles
Emerging data suggest that allospecific Tregs are significantly more powerful than polyclonalexpanded Tregs and with reduced risk of general immunosuppression if used in cell therapy. Chimeric antigen receptors (CARs) are engineered receptors that confer new specificity to T cells, opening the potential of creating allospecific Tregs in the lab [33] . McDonald et al. [34 && ] generated human Tregs expressing second-generation CARs specific to an antigen of the MHC I molecule: HLA-A2. These cells displayed increased proliferation and antigentriggered activation when stimulated via TCR. These CAR-expressing Tregs maintained Treg phenotype cell surface markers [Foxp3, CD25, Helios, cytotoxic T lymphocyte-associated protein 4 (CTLA4)], and latency-associated peptide, epigenetic features (high degree of demethylation pattern in Treg-specific demethylation region of Foxp3 gene), and suppressive function both in-vitro and in-vivo graft versus host disease models [35] . These antigen-specific Tregs had greater suppressive function than control Tregs in-vitro cultures with either T cells or APCs expressing HLA-A2. Thus, the generation of Tregs that express alloantigen-specific CARs could be a promising therapeutic approach to manage allograft rejection, though the polyclonal nature of anti-HLA response posttransplant may pose some challenges.
Exploring targeted drug delivery, Azzi et al. [36] utilized microparticles loaded with tacrolimus and coated with a mAb (clone MECA79) specific to peripheral lymph node addressin, which is expressed by high endothelial venules. The administration of MECA79-bearing particles prolonged cardiac allograft survival and showed significant preferential accumulation in the draining lymph nodes with negligible levels of systemic tacrolimus [36] . Novel approaches to targeted delivery of immunosuppressive drugs are greatly needed to minimize systemic toxicity.
Immune checkpoint inhibitors and allograft
Immune checkpoint inhibitors have been increasingly used in metastatic cancers as more efficacies are proven in different malignancy species. As coinhibitory signals play a critical role in the induction and maintenance of immune regulation, posttransplant, concerns may exist in using these therapies in transplant recipients. Recent case reports documented the successful treatment of metastatic melanoma with anti-CTLA4 (Ipilimumab) in two kidney transplant patients [37] , whereas other studies described severe precipitation of allograft rejection when programmed cell death protein 1 (PD-1) blocking agent was used in kidney transplant recipients (anti-PD-1 alone [38, 39] or in tandem use of anti-CTLA4 and anti-PD-1 [40, 41] ). Enhancing cellular immunity by unleashing T-effector cells can trigger both dormant autoreactive T cells and alloreactive T cells at the same time, leading to immune-related adverse events [42] and allograft rejection, respectively. These limited studies suggest that sole CTLA4 blockade may be well tolerated in selected transplant recipients compared with PD-1 blockade, though further investigation is still required.
Xenotransplantation in the era of CRISPR/ Cas9 technology
Xenotransplantation has been extensively explored as an option to concur organ shortage, however, limitations related to thrombotic complications and concern about transmission of retrovirus has limited its translational application. Recent advances in gene editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR associated protein 9 (Cas9) system, have made this option more realistic. CRISPR/Cas9 system allows simultaneous and precise editing of multiple genes in eukaryotic cells. Using this technology, Mohiuddin et al. [43] performed a pig-to-primate cardiac transplant model utilizing a 1-3 galactosyltransferase gene knockout and human complement regulatory protein CD46 and human thrombomodulin knock-in pigs in combination with a potent immunosuppressive regimen (induction with antithymocyte globulin and anti-CD20 antibody, maintenance with mycophenolate mofetil and intensive dose of anti-CD40). Primate recipients achieved a successful long-term allograft survival (maximum 945 days) without thrombotic complications or humoral rejection. The safety concern of xenotransplant in regards to infections is also becoming within reach. Yang et al. [44] successfully disrupted over 60 porcine endogenous retrovirus pol genes using CRISPR/Cas9, demonstrating the feasibility of this approach to eliminate potentially dangerous retroviruses prior to xenotransplantation.
CONCLUSION
In this review, we highlighted the new advances in understanding and measurement of donor-reactive T-cell responses as well as the role of indirect allorecognition in chronic rejection. Further studies reinforced the importance of different players in the alloimmune response, including innate cells, environmental exposures, and infections in tolerance development. From a clinical perspective, we noted how elucidating molecular signatures of alloimmune response can further lead to new insights onto diagnostic and therapeutic approaches by redefining mechanisms of allograft injury. Finally, we described how novel findings and approaches, including the identification of IL-34, and the use of CRISPR/Cas9 gene editing technologies and CAR T cells, are yielding promising preclinical results in the management of transplant rejection. The efficacy and safety of these strategies in humans will need to be further explored to translate from bench to the clinic and confirm their promise.
